Last reviewed · How we verify
NCT06624787
Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care
NA trial testing Rapid Diagnostic Test in Crimean-Congo Haemorrhagic Fever in 492 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | Liverpool School of Tropical Medicine |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 492 |
| Start date | 4 May 2026 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2027 |
| Sites | 6 locations across Turkey (Türkiye) |
Drugs / interventions tested
- Rapid Diagnostic Test
Conditions studied
- Crimean-Congo Haemorrhagic Fever — all drugs for Crimean-Congo Haemorrhagic Fever →
Sponsor
Liverpool School of Tropical Medicine
Who can join
18 and older, any sex, with Crimean-Congo Haemorrhagic Fever. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Sensitivity and Specificity
Time frame: From the date/time of blood draw of the first participant until all diagnostic results have been received (up to two weeks from blood draw)
To determine the sensitivity and specificity of RDT tests for CCHF in samples of whole blood, serum and capillary blood compared to a gold-standard of PCR for participants that present at 4 endemic sites secondary health care clinics in Turkey.
Sponsor's own description
The goal of this medical device diagnostic evaluation study is to determine if this novel lateral flow device can detect Crimean-Congo Hemorrhagic Fever (CCHF) at the point of care in secondary health care clinics in Turkey. The main outcome is to determine the sensitivity and specificity of the tests for CCHF in samples of whole blood, serum and capillary blood compared to a gold-standard of PCR for participants that present at 4 endemic sites secondary health care clinics in Turkey in 492 adults who are suspected to have been infected with CCHF. The study aims to hopes to achieve at least the minimum required sensitivity of 90 % and specificity of 80 % as required by the WHO.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06624787
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rapid Diagnostic Test
Trials testing the same drug.
- NCT05444790 — Abbott NxTekTM Malaria RDT WHO Prequalification Study · completed
Other Liverpool School of Tropical Medicine trials
Trials by the same sponsor.
- NCT07403318 — Mobile Health Supported Self-care Among Tertiary Education Students in Zimbabwe · NA · not yet recruiting
- NCT06944275 — Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome · not yet recruiting
- NCT07504926 — A Randomised Feasibility Study of CPAP in Large Airway Collapse · NA · not yet recruiting
- NCT07248423 — Start Taking Action for Tuberculosis in Kids · NA · not yet recruiting
- NCT07420881 — Start4All - Start Taking Action for TB Diagnosis (DARE-TB) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06624787 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Liverpool School of Tropical Medicine
- Last refreshed: 5 June 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06624787.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing